Showing results (121-130 of 190) with videos related to
Sort By:
Pageof 19
JMIR Research Protocols|September 20, 2021
The Finding My Way UK Clinical Trial: Adaptation Report and Protocol for a Replication Randomized Controlled Efficacy Trial of a Web-Based Psychological Program to Support Cancer SurvivorsNicholas J Hulbert-Williams, Monica Leslie, Lee Hulbert-Williams, et al.Cell Reports|March 3, 2023
Tspan6 stimulates the chemoattractive potential of breast cancer cells for B cells in an EV- and LXR-dependent mannerGuerman Molostvov, Mariam Gachechiladze, Abeer M Shaaban, et al.Cancers|May 13, 2023
Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma-A Post-hoc Analysis of the GO2 TrialMark A Baxter, Lindsay C Spender, Shaun Walsh, et al.Health Technology Assessment (Winchester, England)|June 5, 2018
The future for diagnostic tests of acute kidney injury in critical care: evidence synthesis, care pathway analysis and research prioritisationPeter S Hall, Elizabeth D Mitchell, Alison F Smith, et al.International Journal of Radiation Oncology, Biology, Physics|December 27, 2011
Impact of screening and risk factors for local recurrence and survival after conservative surgery and radiotherapy for early breast cancer: results from a large series with long-term follow-upIan H Kunkler, Gillian R Kerr, Jeremy S Thomas, et al.The Oncologist|May 17, 2011
Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancerDavid Miles, Henri Roché, Miguel Martin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancerLuca Gianni, Anna Lladó, Giulia Bianchi, et al.Breast Cancer Research : BCR|June 24, 2010
Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancerKaren J Taylor, Andrew H Sims, Liang Liang, et al.Lancet (London, England)|June 11, 2019
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trialHelena M Earl, Louise Hiller, Anne-Laure Vallier, et al.European Journal of Cancer (Oxford, England : 1990)|August 23, 2015
Addressing overtreatment of screen detected DCIS; the LORIS trialAdele Francis, Jeremy Thomas, Lesley Fallowfield, et al.Pageof 19